二氮嗪 (Chinese Wikipedia)
Analysis of information sources in references of the Wikipedia article "二氮嗪" in Chinese language version.
refsWebsite
Global rank
Chinese rank
11th place
332nd place
102nd place
492nd place
149th place
292nd place
low place
low place
7,927th place
5,088th place
18th place
57th place
5,225th place
4,888th place
canada.ca
- Product monograph brand safety updates. Health Canada. 2016-07-06 [2024-04-03].
clinicaltrials.gov
- Clinical trial number NCT05532020 for "An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities" at ClinicalTrials.gov
doi.org
- Doyle ME, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacological Reviews. March 2003, 55 (1): 105–131. PMID 12615955. S2CID 11121340. doi:10.1124/pr.55.1.7.
- van Hamersvelt HW, Kloke HJ, de Jong DJ, Koene RA, Huysmans FT. Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention?. Journal of Hypertension. August 1996, 14 (8): 1041–1045. PMID 8884561. S2CID 3283469. doi:10.1097/00004872-199608000-00016.
- Huang Q, Bu S, Yu Y, Guo Z, Ghatnekar G, Bu M, Yang L, Lu B, Feng Z, Liu S, Wang F. Diazoxide prevents diabetes through inhibiting pancreatic beta-cells from apoptosis via Bcl-2/Bax rate and p38-beta mitogen-activated protein kinase. Endocrinology. January 2007, 148 (1): 81–91. PMID 17053028. doi:10.1210/en.2006-0738
.
- Randle JC, Biton C, Lepagnol JM. Allosteric potentiation by diazoxide of AMPA receptor currents and synaptic potentials. European Journal of Pharmacology. November 1993, 247 (3): 257–265. PMID 8307099. doi:10.1016/0922-4106(93)90193-D.
- Panten U, Burgfeld J, Goerke F, Rennicke M, Schwanstecher M, Wallasch A, Zünkler BJ, Lenzen S. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets. Biochemical Pharmacology. April 1989, 38 (8): 1217–1229. PMID 2650685. doi:10.1016/0006-2952(89)90327-4.
- Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, Felner EI, Bird LM, Shoemaker AH, Angulo M, Butler MG, Stevenson D, Goldstone AP, Wilding J, Lah M, Shaikh MG, Littlejohn E, Abuzzahab MJ, Fleischman A, Hirano P, Yen K, Cowen NM, Bhatnagar A. Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study. Obesity. February 2024, 32 (2): 252–261. PMID 37919617. S2CID 264973612. doi:10.1002/oby.23928 . hdl:10044/1/107689 .
- Kimonis V, Surampalli A, Wencel M, Gold JA, Cowen NM. A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome. PLOS ONE. 23 September 2019, 14 (9): e0221615. Bibcode:2019PLoSO..1421615K. PMC 6756513 . PMID 31545799. doi:10.1371/journal.pone.0221615 .
- Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, Felner EI, Bird LM, Shoemaker AH, Angulo M, Butler MG, Stevenson D, Abuzzahab J, Barrett T, Lah M, Littlejohn E, Mathew V, Cowen NM, Bhatnagar A. Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial. The Journal of Clinical Endocrinology and Metabolism. June 2023, 108 (7): 1676–1685. PMC 10271219 . PMID 36639249. doi:10.1210/clinem/dgad014.
drugs.com
- Diazoxide Monograph for Professionals. Drugs.com. [11 October 2019] （英语）.
fda.gov
handle.net
hdl.handle.net
- World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. hdl:10665/345533 . WHO/MHP/HPS/EML/2021.02.
- Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, Felner EI, Bird LM, Shoemaker AH, Angulo M, Butler MG, Stevenson D, Goldstone AP, Wilding J, Lah M, Shaikh MG, Littlejohn E, Abuzzahab MJ, Fleischman A, Hirano P, Yen K, Cowen NM, Bhatnagar A. Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study. Obesity. February 2024, 32 (2): 252–261. PMID 37919617. S2CID 264973612. doi:10.1002/oby.23928 . hdl:10044/1/107689 .
harvard.edu
ui.adsabs.harvard.edu
- Kimonis V, Surampalli A, Wencel M, Gold JA, Cowen NM. A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome. PLOS ONE. 23 September 2019, 14 (9): e0221615. Bibcode:2019PLoSO..1421615K. PMC 6756513 . PMID 31545799. doi:10.1371/journal.pone.0221615 .
nih.gov
ncbi.nlm.nih.gov
- Doyle ME, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacological Reviews. March 2003, 55 (1): 105–131. PMID 12615955. S2CID 11121340. doi:10.1124/pr.55.1.7.
- van Hamersvelt HW, Kloke HJ, de Jong DJ, Koene RA, Huysmans FT. Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention?. Journal of Hypertension. August 1996, 14 (8): 1041–1045. PMID 8884561. S2CID 3283469. doi:10.1097/00004872-199608000-00016.
- Huang Q, Bu S, Yu Y, Guo Z, Ghatnekar G, Bu M, Yang L, Lu B, Feng Z, Liu S, Wang F. Diazoxide prevents diabetes through inhibiting pancreatic beta-cells from apoptosis via Bcl-2/Bax rate and p38-beta mitogen-activated protein kinase. Endocrinology. January 2007, 148 (1): 81–91. PMID 17053028. doi:10.1210/en.2006-0738 .
- Randle JC, Biton C, Lepagnol JM. Allosteric potentiation by diazoxide of AMPA receptor currents and synaptic potentials. European Journal of Pharmacology. November 1993, 247 (3): 257–265. PMID 8307099. doi:10.1016/0922-4106(93)90193-D.
- Panten U, Burgfeld J, Goerke F, Rennicke M, Schwanstecher M, Wallasch A, Zünkler BJ, Lenzen S. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets. Biochemical Pharmacology. April 1989, 38 (8): 1217–1229. PMID 2650685. doi:10.1016/0006-2952(89)90327-4.
- Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, Felner EI, Bird LM, Shoemaker AH, Angulo M, Butler MG, Stevenson D, Goldstone AP, Wilding J, Lah M, Shaikh MG, Littlejohn E, Abuzzahab MJ, Fleischman A, Hirano P, Yen K, Cowen NM, Bhatnagar A. Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study. Obesity. February 2024, 32 (2): 252–261. PMID 37919617. S2CID 264973612. doi:10.1002/oby.23928 . hdl:10044/1/107689 .
- Kimonis V, Surampalli A, Wencel M, Gold JA, Cowen NM. A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome. PLOS ONE. 23 September 2019, 14 (9): e0221615. Bibcode:2019PLoSO..1421615K. PMC 6756513 . PMID 31545799. doi:10.1371/journal.pone.0221615 .
- Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, Felner EI, Bird LM, Shoemaker AH, Angulo M, Butler MG, Stevenson D, Abuzzahab J, Barrett T, Lah M, Littlejohn E, Mathew V, Cowen NM, Bhatnagar A. Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial. The Journal of Clinical Endocrinology and Metabolism. June 2023, 108 (7): 1676–1685. PMC 10271219 . PMID 36639249. doi:10.1210/clinem/dgad014.
pediatriconcall.com
- Diazoxide. Padiatric Oncall. [2024-07-02].
rxlist.com
- DIAZOXIDE. RxList. [2024-07-02].
sciencedirect.com
- Farris, F.F. Encyclopedia of Toxicology Reference Work • Third Edition • 2014 https://www.sciencedirect.com/topics/chemistry/diazoxide. [20240702]. 缺少或
|title=为空 (帮助)
semanticscholar.org
api.semanticscholar.org
- Doyle ME, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacological Reviews. March 2003, 55 (1): 105–131. PMID 12615955. S2CID 11121340. doi:10.1124/pr.55.1.7.
- van Hamersvelt HW, Kloke HJ, de Jong DJ, Koene RA, Huysmans FT. Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention?. Journal of Hypertension. August 1996, 14 (8): 1041–1045. PMID 8884561. S2CID 3283469. doi:10.1097/00004872-199608000-00016.
- Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, Felner EI, Bird LM, Shoemaker AH, Angulo M, Butler MG, Stevenson D, Goldstone AP, Wilding J, Lah M, Shaikh MG, Littlejohn E, Abuzzahab MJ, Fleischman A, Hirano P, Yen K, Cowen NM, Bhatnagar A. Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study. Obesity. February 2024, 32 (2): 252–261. PMID 37919617. S2CID 264973612. doi:10.1002/oby.23928 . hdl:10044/1/107689 .